Sensyne Health PLC (LON:SENS) said it has signed a production contract with the UK’s Department of Health & Social Care (DHSC) to use the company’s MagnifEye artificial intelligence (AI) technology to read coronavirus (COVID-19) lateral flow diagnostics tests as part of the country’s asymptomatic testing programme.
The clinical AI technology firm said the contract with DHSC is for a phased nationwide rollout over a three month period in care homes, GP practices and selected private sector organisations with large workforces.
Sensyne added that revenues from the deal will be shared with Excalibur Health Systems under the terms of an exclusive agreement between the two companies.
“This is a significant commercial milestone in Sensyne’s development and underlines the potential of our world-class expertise in clinical AI applied to diagnostic testing. We are delighted to be working with the Department of Health & Social Care to support the UK’s national COVID testing programme, which is making a huge impact in helping the nation to recover from the pandemic”, Sensyne chief executive Paul Drayson said in a statement.